Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with statutory auditor Deloitte Haskins & Sells issuing an unmodified (clean) opinion. The board recommended a final dividend of Rs. 18 per share (1800%) on a face value of Rs. 1, subject to shareholder approval at the 47th AGM on August 28, 2025, with the record date set as August 14, 2025. The board also appointed M/s. RVR & Associates as Secretarial Auditors for a 5-year term starting April 1, 2025, and amended several governance policies including those on related party transactions, insider trading, and whistle blower protection.
A clean audit opinion signals healthy financial reporting, and the Rs. 18 final dividend offers a strong payout to shareholders. The results document itself does not include detailed revenue or profit figures, so investors will need the attached financial statements and investor presentation to assess earnings performance.